Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Anti-CAR T-cell immune response

Sara Ghorashian • 15 Jun 2019
EHA 2019
Acute Lymphoblastic Leukemia Leukemia

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, discusses the issue of CAR T-cell persistence at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Sara Ghorashian

1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals